Cancer

Clinical Research Studies in Cancer

Bladder Cancer

Does the use of a post-operative pedometer impact the return of bowel function and narcotic use following radical cystectomy?
Principal Investigator: Alvaro Lucioni, MD
Status: Enrolling

 

---

A prospective, non-interventional study to assess the prevalence of PD-L1 expression in the first-line setting of locally advanced/unresectable or metastatic urothelial carcinoma
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (Ambassador) versus observation
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment 

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) 
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

Phase III, Randomized, Open-Label, Controlled, Multi_Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer
Principal Investigator: Joseph Rosales, MD
Status: Closed to Enrollment

Blood Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Principal Investigator: David Aboulafia, MD
Status: Enrolling

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Principal Investigator: David Aboulafia, MD
Status: Enrolling

 

---

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Randomized, Open-label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodkin Lymphoma
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

Phase 3 Randomized Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab/Placebo Plus Lenalidomide with Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma Grade 1-3a or Marginal Zone Lymphoma
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

SWOG S0016 A Phase III Trial of CHOP Plus Rituximab versus CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for the Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Brain Cancer

A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms Short Title:  STaRT
Principal Investigator: Huong Pham, MD
Status: Enrolling

A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
Principal Investigator: Huong Pham, MD
Status: Enrolling

Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in MGMT+ GBM
Principal Investigator: John Paul Flores, MD 
Status: Enrolling

 

---

Randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed GBM with MGMT promoter hypermethylation
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

Breast Cancer

Intra-Operative Radiotherapy after breast conserving therapy in the treatment of early stage breast cancer
Principal Investigator: Huong Pham, MD
Status: Enrolling

 

---

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A PHASE III CLINICAL TRIAL COMPARING TRASTUZUMAB GIVEN CONCURRENTLY WITH RADIATION THERAPY AND RADIATION THERAPY ALONE FOR WOMEN WITH HER2-POSITIVE DUCTICAL CARCINOMA IN SITU RESECTED BY LUMPECTOMY
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A RANDOMIZED, PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MK-3475 (PEMBROLIZUMAB) AS ADJUVANT THERAPY FOR TRIPLE RECEPTOR-NEGATIVE BREAST CANCER WITH ≥ 1 CM RESIDUAL INVASIVE CANCER OR POSITIVE LYMPH NODES (ypN+) AFTER NEOADJUVANT CHEMOTHERAPY
Principal Investigator: Meaghan O'Malley, MD
Status: Closed to Enrollment

Elacestrant monotherapy vs. standard of care for the treatment of patients with ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy: a phase 3 randomized, open-label, active-controlled, multicenter Trial (EMERALD)
Principal Investigator: Meaghan O'Malley, MD
Status: Closed to Enrollment

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer
Principal Investigator: Nanette Robinson, MD
Status: Closed to Enrollment

RANDOMIZED PHASE III TRIAL OF PACLITAXEL COMBINED WITH TRASTUZUMAB, LAPATINIB, OR BOTH AS NEOADJUVANT TREATMENT OF HER2-POSITIVE PRIMARY BREAST CANCER
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Cancer Non-Specific

A Phase 1/1b Study of ASP2074 in Participants with Metastatic or Locally Advanced Solid Tumors
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN LABEL TREATMENT PERIOD
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

A prospective observational cohort study to assess miRNA 371 for outcome prediction in patients with newly diagnosed germ cell tumors
Principal Investigator: John Paul Flores, MD
Status: Enrolling

Characterization of the peripheral blood signature in patients treated with PD1/PDL-1 Checkpoint Inhibitors
Principal Investigator: John Paul Flores, MD
Status: Enrolling

EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III TrialEA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Principal Investigator: Bruce Lin, MD
Status: Enrolling

Secondary Use Donor Derived APL sample requested by Stanford investigator - Molecular, Antigenic, and Genetic Characterization of Inflammatory and Neoplastic Cellular Subsets in Hematopoietic Neoplasms
Principal Investigator: Russell Dorer, MD
Status: Enrolling 

Virginia Mason Medical Center and Benaroya Research Institute Tumor Tissue Repository (VM-BRITE) Sample Collection Protocol
Principal Investigator: Christopher Gault, MD 
Status: Enrolling

 

---

Evaluating The Use of a Smartphone Application and Biosensor by Cancer Patients Undergoing Systemic Treatments
Principal Investigator: Mark Beiter, DO
Status: Closed to Enrollment

GRAIL-001 The Circulating Cell-free Genome Atlas (CCGA) Study
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

Immune Checkpoint Inhibitor (ICI) Cancer Research Protocol
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

Phase III Trial of Radiotherapy Plus Cetuximab versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Program for the assessment of clinical cancer tests (PACCT-1):  Trial assigning individualized options for treatment:  The TAILORx Trial
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Colorectal Cancer

A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
Principal Investigator: Bruce Lin, MD
Status: Enrolling

A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Principal Investigator: Bruce Lin, MD
Status: Enrolling

HAI Consortium Research Network: Registry of Hepatic Arterial Infusion (HAI)
Principal Investigator: Lauren Wancata, MD
Status: Enrolling

Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Clinical Trial
Principal Investigator: Nicholas Agoff, MD
Status: Enrolling

 

---

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III –Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Under
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Pilot Protocol Evaluating Safety of the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HAI) Chemotherapy in patients with advanced Colorectal Carcinoma or Cholangiocarcinoma
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

Colorectal Polyp Detection Comparing Computer Assisted Colonoscopy with Conventional Colonoscopy
Principal Investigator: Joanna Law, MD
Status: Closed to Enrollment

NEOADJUVANT CHEMOTHERAPY, EXCISION AND OBSERVATION FOR EARLY RECTAL CANCER The NEO Trial.
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

Randomized trial of standard chemotherapy alone or combined with Atezolizumab as adjuvant therapy for patients with Stage III colon cancer and deficient DNA mismatch repair.
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

SHOrt course Radiation and TAS102 chemotherapy in operable rectal cancer, SHORT Trial
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

 

Gastroesophageal Cancer

Evaluation of the Lasting Symptoms After Esophageal Resection (LASER) questionnaire in esophageal disease
Principal Investigator: Donald Low, MD
Status: Enrolling

Phase 2 study of ZW25 plus first-line combination chemotherapy in HER2-Expression gastroesophageal adenocarcinoma (GEA)
Principal Investigator: Bruce Lin, MD
Status: Enrolling

 

---

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

Influence of Nutrition and SarcoPenia on Esophageal Cancer outcomes (INSPECT study)
Principal Investigator: Donald Low, MD
Status: Closed to Enrollment

Temporal variation in exhaled volatile organic compounds in response to therapeutic intervention in esophageal cancer patients
Principal Investigator: Donald Low, MD
Status: Closed to Enrollment

Gynecologic Cancer

CAN DIET AND EXERCISE MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL?
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Head and Neck Cancer

A Phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Principal Investigator: Meaghan O'Malley, MD
Status: Closed to Enrollment

Hepatobiliary Cancer (Liver and Biliary Tract)

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY 4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Principal Investigator: Bruce Lin, MD
Status: Enrolling

A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Principal Investigator: Bruce Lin, MD
Status: Enrolling

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement (FIGHT-302)
Principal Investigator: Bruce Lin, MD
Status: Enrolling

 

---

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

A Single Arm Phase Ib/II Multi-Center Study of Nivolumab in Combination with nanoliposomal-Irinotecan, 5-Fluorouracil, and Leucovorin as Second Line Therapy for Patients with Advanced Biliary Tract Cancer
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

A Single-arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
Principal Investigator: Bruce Lin, MD
Status: Closed to Enrollment

HIV/AIDS Malignancies

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
Principal Investigator: David Aboulafia, MD
Status: Enrolling

AMC-101, A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Principal Investigator: David Aboulafia, MD
Status: Enrolling

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AIDS Malignancy Consortium
Principal Investigator: David Aboulafia, MD
Status: Enrolling

 

---

AMC-087: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

AMC-088: A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-positive
Principal Investigator: David Aboulafia, MD
Status: Enrolling

ANCHOR: Anal Cancer/HSIL Outcomes Research Study
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

Kaposi Sarcoma

Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma
Principal Investigator: David Aboulafia, MD
Status: Enrolling

 

---

A Phase II Study of sEphB4-HAS in Kaposi Sarcoma
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma: A Trial of the AIDS Malignancy Consortium (AMC)
Principal Investigator: David Aboulafia, MD
Status: Closed to Enrollment

Kidney Cancer

EVEREST EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Lung Cancer

ATEZOLIZUMAB + SBRT VERSUS SBRT ALONE IN HIGH RISK, EARLY STAGE NSCLC
Principal Investigator: Joseph Rosales, MD
Status: Enrolling

 

---

A Phase II Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK)
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (=4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC).
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Neuroendocrine Tumors

An International, Non-Interventional, Post-Authorization Long-Term Safety Study of Lutathera®, in Patients with Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours (SALUS study).
Principal Investigator: Bruce Lin, MD
Status: Enrolling

Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus (CABINET)
Principal Investigator: Bruce Lin, MD
Status: Enrolling

Pancreatic Cancer

A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with Avutometinib (VS-6766) and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

Alternating neoadjuvant Gemcitabine-Nab-Paclitaxel and nal-IRI with 5-Fluorouracil and folinic acid (Leucovorin) regimens in resectable and borderline resectable pancreatic cancer, A Pilot Study
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

Analysis of Health Outcome of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

PRECISION PROMISE PLATFORM TRIAL FOR METASTATIC PANCREATIC CANCER
Principal Investigator: Vincent Picozzi, MD
Status: Enrolling

 

---

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Principal Investigator: Vincent Picozzi, MD
Status: Closed to Enrollment

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
Principal Investigator: Vincent Picozzi, MD
Status: Closed to Enrollment

Distal pancreatectomy, minimally invasive or open, for malignancy (DIPLOMA): a randomized controlled, multicenter, non-inferiority trial.
Principal Investigator: Scott Helton, MD
Status: Closed to Enrollment

GEMCITABINE AND NAB-PACLITAXEL IN PANCREATIC ADENOCARCINOMA WITH POSITIVE PERITONEAL CYTOLOGY AS A SOLE METASTATIC SITE, A PILOT STUDY
Principal Investigator: Vincent Picozzi, MD
Status: Closed to Enrollment

PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic aden
Principal Investigator: Vincent Picozzi, MD
Status: Closed to Enrollment

VM-BRI repository for early detection of pancreas cancer (VM-BRIDPAN)
Principal Investigator: Margaret Mandelson, PhD
Status: Closed to Enrollment

 

Prostate Cancer

A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

NRG-GU009: PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
Principal Investigator: Huong Pham, MD and John Paul Flores, MD
Status: Enrolling

NRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)
Principal Investigator: Huong Pham, MD and John Paul Flores, MD
Status: Enrolling

 

---

A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-Specific
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Principal Investigator: Joseph Rosales, MD
Status: Closed to Enrollment

A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A PHASE III TRIAL OF SHORT TERM ANDROGEN DEPRIVATION WITH PELVIC LYMPH NODE OR PROSTATE BED ONLY RADIOTHERAPY (SPPORT) IN PROSTATE CANCER PATIENTS WITH A RISING PSA AFTER RADICAL PROSTATECTOMY.
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

A randomized phase 3, open-label trial of sipuleucel-T administered to patients on active surveillance for newly diagnosed prostate cancer.
Principal Investigator: John Paul Flores, MD
Status: Closed to Enrollment

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Does the Use of a Post-Operative Pedometer Affect Rate of Return of Bowel Function and Narcotic Use Following Radical Prostatectomy
Principal Investigator: Una Lee, MD
Status: Closed to Enrollment

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment

Skin Cancer

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-risk Melanoma
Principal Investigator: Huong Pham, MD
Status: Closed to Enrollment